Metropolis HealthcareNSE:METROPOLIS +1.41%95 ROE % is 13.46% as of Mar. 2026, which is 50% below its 10-year median of 26.96. GuruFocus rates NSE:METROPOLIS with a GF Score™ of 95/100 and a GF Value™ of ₹588.25 (Fairly Valued). The stock has 4 warning signs investors should review. Among 201 Medical Diagnostics & Research companies, Metropolis Healthcare ranks better than 81.09% on this metric.
The historical rank and industry rank for Metropolis Healthcare's ROE % or its related term are showing as below:
NSE:METROPOLIS'
s ROE % Range Over the Past 10 Years
Min: 11.95 Med: 26.96 Max: 33.78
Current: 13.33
During the past 11 years, Metropolis Healthcare's highest ROE % was 33.78%. The lowest was 11.95%. And the median was 26.96%.
NSE:METROPOLIS's ROE % is ranked better than 81.09% of 201
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.24
vs NSE:METROPOLIS: 13.33
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:METROPOLIS vs TMO, DHR, IDXX: ROE % Comparison
For the Diagnostics & Research subindustry, Metropolis Healthcare's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Metropolis Healthcare ROE % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Metropolis Healthcare's ROE % distribution charts can be found below:
* The bar in red indicates where Metropolis Healthcare's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Metropolis Healthcare (NSE:METROPOLIS) has a ROE % of 13.46% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Metropolis Healthcare and its competitors. This is 50% below median its historical median of 26.96. Over the past decade, Metropolis Healthcare's ROE % has ranged from 11.95 to 33.78. According to the industry distribution chart, Metropolis Healthcare ranks #38 out of 201 companies in the Medical Diagnostics & Research industry, placing it in the top 18.9%.
Is Metropolis Healthcare's ROE % too high?
Metropolis Healthcare's current ROE % of 13.46% is 50% below median its 10-year median of 26.96. Over the past 10 years, this metric has ranged from a low of 11.95 to a high of 33.78. Based on the distribution chart, Metropolis Healthcare ranks #38 out of 201 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Metropolis Healthcare has a GF Score™ of 95/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Metropolis Healthcare's ROE % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Metropolis Healthcare ranks #38 out of 201 companies for ROE %. This places Metropolis Healthcare in the top 19% of its industry — outperforming the majority of peers. Historically, Metropolis Healthcare's own ROE % has ranged from 11.95 to 33.78 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Diagnostics & Research company?
A good ROE % depends on the Medical Diagnostics & Research industry context. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Metropolis Healthcare and its competitors. Metropolis Healthcare's current ROE % is 13.46%, which is 50% below median its own 10-year median of 26.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Metropolis Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Metropolis Healthcare (NSE:METROPOLIS) is currently considered Fairly Valued. The stock's GF Value™ is ₹588.25, compared to a current price of ₹567.95 — trading 3.5% below its estimated fair value. The current ROE % is 13.46%, which is 50% below median its 10-year median of 26.96. Metropolis Healthcare's overall GF Score™ is 95/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Metropolis Healthcare (NSE:METROPOLIS), the current ROE % is 13.46% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Metropolis Healthcare (NSE:METROPOLIS) Overvalued in 2026?
Based on GuruFocus' analysis, Metropolis Healthcare stock appears to be undervalued.
The current stock price of ₹567.95 is trading 3.5% below its estimated GF Value™ of ₹588.25.
GuruFocus considers Metropolis Healthcare to be Fairly Valued.
Key valuation signals for NSE:METROPOLIS:
ROE %: 13.46% (50% below median its 10-year median of 26.96)
GF Value™: ₹588.25 vs. price of ₹567.95 (3.5% below fair value)
No single metric tells the full story. See the NSE:METROPOLIS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Metropolis Healthcare Ltd is a diagnostic company in India. It offers a comprehensive range of clinical laboratory tests and profiles, which are used for the prediction, early detection, diagnostic screening, confirmation, and monitoring of the disease. It also offers analytical and supports services to clinical research organizations for their clinical research projects. Pathology service is the only principal activity and reportable segment from which the Group generates its revenue.
95GF Score
Get the complete analysis for NSE:METROPOLIS
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:METROPOLIS has been successfully added to your 
